RA
LPCN icon

Rosalind Advisors’s Lipocine LPCN Stock Holding History

Rosalind Advisors’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-221,616
Closed -$1.77M – 39
2026
Q1 		$1.77M Buy
+221,616
New +$1.93M 0.71% 26

Other funds holding LPCN

SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Rosalind Advisors's LPCN Position: Q2 2026 in Review

Rosalind Advisors sold out of Lipocine (LPCN) in Q2 2026, closing a stake of 221,616 shares — an estimated $1.77M sold.

Rosalind Advisors first reported a position in LPCN in Q1 2026 and held it in 1 quarter. The position peaked at $1.77M in Q1 2026. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

  • Rosalind Advisors reported no remaining Lipocine position as of Q2 2026 after selling out during the quarter.
  • Rosalind Advisors sold 221,616 Lipocine shares in Q2 2026, an estimated $1.77M.
  • Rosalind Advisors first reported a position in Lipocine in Q1 2026 and held it in 1 quarter.
  • Rosalind Advisors's Lipocine position peaked at $1.77M in Q1 2026.
  • 36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on Rosalind Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.